255 related articles for article (PubMed ID: 26405169)
21. Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT.
Castellucci P; Pou Ucha J; Fuccio C; Rubello D; Ambrosini V; Montini GC; Pettinato V; Malizia C; Lodi F; Fanti S
J Nucl Med; 2011 Jun; 52(6):886-90. PubMed ID: 21571796
[TBL] [Abstract][Full Text] [Related]
22. Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions.
Cingarlini S; Ortolani S; Salgarello M; Butturini G; Malpaga A; Malfatti V; DʼOnofrio M; Davì MV; Vallerio P; Ruzzenente A; Capelli P; Citton E; Grego E; Trentin C; De Robertis R; Scarpa A; Bassi C; Tortora G
Pancreas; 2017 Jan; 46(1):42-47. PubMed ID: 27906872
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of (68)Ga-DOTANOC PET/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors.
Sharma P; Arora S; Dhull VS; Naswa N; Kumar R; Ammini AC; Bal C
Abdom Imaging; 2015 Feb; 40(2):299-309. PubMed ID: 25134801
[TBL] [Abstract][Full Text] [Related]
24. The Correlation Between [
Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
[TBL] [Abstract][Full Text] [Related]
25. Comparison of renal uptake of 68Ga-DOTANOC PET/CT and estimated glomerular filtration rate before and after peptide receptor radionuclide therapy in patients with metastatic neuroendocrine tumours.
Kaewput C; Vinjamuri S
Nucl Med Commun; 2016 Dec; 37(12):1325-1332. PubMed ID: 27612032
[TBL] [Abstract][Full Text] [Related]
26. Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT.
Froeling V; Röttgen R; Collettini F; Rothe J; Hamm B; Brenner W; Schreiter N
Q J Nucl Med Mol Imaging; 2014 Sep; 58(3):310-8. PubMed ID: 25265251
[TBL] [Abstract][Full Text] [Related]
27. The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers.
Haidar M; Shamseddine A; Panagiotidis E; Jreige M; Mukherji D; Assi R; Abousaid R; Ibrahim T; Haddad MM; Vinjamuri S
Nucl Med Commun; 2017 Feb; 38(2):170-177. PubMed ID: 27922538
[TBL] [Abstract][Full Text] [Related]
28. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
[TBL] [Abstract][Full Text] [Related]
29. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC?
Öksüz MÖ; Winter L; Pfannenberg C; Reischl G; Müssig K; Bares R; Dittmann H
Diagn Interv Imaging; 2014 Mar; 95(3):289-300. PubMed ID: 24034971
[TBL] [Abstract][Full Text] [Related]
30. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.
Virgolini I; Gabriel M; Kroiss A; von Guggenberg E; Prommegger R; Warwitz B; Nilica B; Roig LG; Rodrigues M; Uprimny C
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2072-83. PubMed ID: 27174220
[TBL] [Abstract][Full Text] [Related]
31. Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors.
Ansquer C; Touchefeu Y; Faivre-Chauvet A; Leux C; Le Bras M; Régenet N; Fleury V; Maucherat B; Senellart H; Guyetant S; Carlier T; Scotet-Cérato E; Rauscher A; Frampas E; Kraeber-Bodéré F
Clin Nucl Med; 2021 Mar; 46(3):181-186. PubMed ID: 33315677
[TBL] [Abstract][Full Text] [Related]
32. Clinical and Prognostic Value of PET/CT Imaging with Combination of
Zhang P; Yu J; Li J; Shen L; Li N; Zhu H; Zhai S; Zhang Y; Yang Z; Lu M
Contrast Media Mol Imaging; 2018; 2018():2340389. PubMed ID: 29681780
[TBL] [Abstract][Full Text] [Related]
33. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Contrast-Enhanced CT + CT Enterography and 68Ga-DOTANOC PET/CT in Gastroenteropancreatic Neuroendocrine Tumors.
Sharma A; Das CJ; Makharia GK; Arora G; Kumar R
Clin Nucl Med; 2020 Nov; 45(11):848-853. PubMed ID: 32657875
[TBL] [Abstract][Full Text] [Related]
35. Clinical role of fludeoxyglucose (18F) positron emission tomography/computed tomography (
Matsumoto T; Okabe H; Yamashita YI; Yusa T; Itoyama R; Nakao Y; Yamao T; Umzaki N; Tsukamoto M; Kitano Y; Miyata T; Arima K; Nitta H; Hayashi H; Imai K; Chikamoto A; Baba H
Surg Today; 2019 Jan; 49(1):21-26. PubMed ID: 30128759
[TBL] [Abstract][Full Text] [Related]
36. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
[TBL] [Abstract][Full Text] [Related]
37. Molecular response assessed by (68)Ga-DOTANOC and survival after (90)Y microsphere therapy in patients with liver metastases from neuroendocrine tumours.
Filippi L; Scopinaro F; Pelle G; Cianni R; Salvatori R; Schillaci O; Bagni O
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):432-40. PubMed ID: 26323577
[TBL] [Abstract][Full Text] [Related]
38. 68Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma.
Sharma P; Thakar A; Suman K C S; Dhull VS; Singh H; Naswa N; Reddy RM; Karunanithi S; Kumar R; Kumar R; Malhotra A; Bal C
J Nucl Med; 2013 Jun; 54(6):841-7. PubMed ID: 23520216
[TBL] [Abstract][Full Text] [Related]
39. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors.
Haug AR; Auernhammer CJ; Wängler B; Schmidt GP; Uebleis C; Göke B; Cumming P; Bartenstein P; Tiling R; Hacker M
J Nucl Med; 2010 Sep; 51(9):1349-56. PubMed ID: 20720050
[TBL] [Abstract][Full Text] [Related]
40. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.
Ambrosini V; Tomassetti P; Castellucci P; Campana D; Montini G; Rubello D; Nanni C; Rizzello A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1431-8. PubMed ID: 18418596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
